Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.

ABSTRACT:

Background

Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed. On-drug patient perspectives and experiences are valuable to understand and manage this patient population.

Objective

The objective of this study was to examine perspectives and experiences of patients receiving dalfampridine-ER in a real-world setting.

Methods

Step Together, an ongoing program that captures real-world patient experience with dalfampridine-ER treatment, consists of a survey administered at baseline (before dalfampri

SUBMITTER: Crayton H 

PROVIDER: S-EPMC4445766 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature